Myriad Genetics (MYGN) Competitors $5.18 +0.19 (+3.70%) As of 03:10 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MYGN vs. FOLD, BCRX, CLDX, DVAX, INVA, MNKD, NVAX, OPK, GERN, and RGLSShould you be buying Myriad Genetics stock or one of its competitors? The main competitors of Myriad Genetics include Amicus Therapeutics (FOLD), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), Innoviva (INVA), MannKind (MNKD), Novavax (NVAX), OPKO Health (OPK), Geron (GERN), and Regulus Therapeutics (RGLS). These companies are all part of the "biotechnology" industry. Myriad Genetics vs. Its Competitors Amicus Therapeutics BioCryst Pharmaceuticals Celldex Therapeutics Dynavax Technologies Innoviva MannKind Novavax OPKO Health Geron Regulus Therapeutics Amicus Therapeutics (NASDAQ:FOLD) and Myriad Genetics (NASDAQ:MYGN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations. Does the media refer more to FOLD or MYGN? In the previous week, Amicus Therapeutics had 12 more articles in the media than Myriad Genetics. MarketBeat recorded 15 mentions for Amicus Therapeutics and 3 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 1.49 beat Amicus Therapeutics' score of 0.94 indicating that Myriad Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amicus Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Myriad Genetics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is FOLD or MYGN more profitable? Amicus Therapeutics has a net margin of -5.41% compared to Myriad Genetics' net margin of -12.20%. Amicus Therapeutics' return on equity of 4.67% beat Myriad Genetics' return on equity.Company Net Margins Return on Equity Return on Assets Amicus Therapeutics-5.41% 4.67% 1.05% Myriad Genetics -12.20%-4.95%-3.39% Do analysts prefer FOLD or MYGN? Amicus Therapeutics currently has a consensus price target of $16.22, suggesting a potential upside of 167.47%. Myriad Genetics has a consensus price target of $14.38, suggesting a potential upside of 183.22%. Given Myriad Genetics' higher probable upside, analysts clearly believe Myriad Genetics is more favorable than Amicus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amicus Therapeutics 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.70Myriad Genetics 2 Sell rating(s) 10 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.13 Do insiders and institutionals hold more shares of FOLD or MYGN? 99.0% of Myriad Genetics shares are owned by institutional investors. 2.2% of Amicus Therapeutics shares are owned by company insiders. Comparatively, 2.1% of Myriad Genetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has preferable earnings and valuation, FOLD or MYGN? Amicus Therapeutics has higher earnings, but lower revenue than Myriad Genetics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmicus Therapeutics$528.29M3.54-$56.11M-$0.09-67.39Myriad Genetics$837.60M0.56-$127.30M-$1.12-4.53 Which has more risk and volatility, FOLD or MYGN? Amicus Therapeutics has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 1.91, indicating that its stock price is 91% more volatile than the S&P 500. SummaryAmicus Therapeutics beats Myriad Genetics on 10 of the 16 factors compared between the two stocks. Get Myriad Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MYGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MYGN vs. The Competition Export to ExcelMetricMyriad GeneticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$467.81M$2.92B$5.56B$9.30BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-4.5320.3828.6319.67Price / Sales0.56304.58439.23185.66Price / Cash5.2243.1536.0257.93Price / Book0.667.738.185.64Net Income-$127.30M-$55.11M$3.23B$257.73M7 Day Performance-11.21%0.65%-0.20%0.21%1 Month Performance3.23%8.17%5.43%8.47%1 Year Performance-81.46%-2.67%26.39%13.93% Myriad Genetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MYGNMyriad Genetics4.5754 of 5 stars$5.19+3.7%$14.38+177.4%-81.2%$476.11M$837.60M-4.612,700News CoveragePositive NewsFOLDAmicus Therapeutics4.0888 of 5 stars$6.05-0.8%$16.22+168.1%-44.4%$1.86B$528.29M-67.21480BCRXBioCryst Pharmaceuticals4.1844 of 5 stars$8.76-2.0%$16.70+90.6%+21.4%$1.83B$450.71M-33.69530Analyst RevisionCLDXCelldex Therapeutics2.482 of 5 stars$20.98-4.6%$50.11+138.9%-42.2%$1.39B$7.56M-7.77150News CoverageAnalyst RevisionDVAXDynavax Technologies4.4396 of 5 stars$10.30+0.3%$24.00+133.0%-1.1%$1.24B$277.25M-19.81350Positive NewsINVAInnoviva4.0518 of 5 stars$18.91-1.6%$55.00+190.9%+18.5%$1.19B$369.84M-18.72100News CoverageAnalyst ForecastAnalyst RevisionMNKDMannKind2.7205 of 5 stars$3.54-1.7%$10.33+191.9%-34.0%$1.08B$285.50M35.40400Positive NewsAnalyst ForecastGap UpNVAXNovavax4.3202 of 5 stars$6.61-2.8%$17.00+157.2%-54.5%$1.07B$682.16M2.491,990Positive NewsOPKOPKO Health4.1824 of 5 stars$1.34-1.5%$2.75+105.2%-7.0%$1.06B$713.10M-19.142,997Positive NewsGERNGeron3.4153 of 5 stars$1.37-4.2%$5.06+269.5%-74.3%$872.58M$76.99M-6.5270News CoverageRGLSRegulus Therapeutics1.6356 of 5 stars$8.16flat$8.50+4.2%N/A$564.92MN/A-11.1830 Related Companies and Tools Related Companies FOLD Alternatives BCRX Alternatives CLDX Alternatives DVAX Alternatives INVA Alternatives MNKD Alternatives NVAX Alternatives OPK Alternatives GERN Alternatives RGLS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MYGN) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredDrilling With a $3.5B Discovery Partner in Its CornerA small-cap explorer is about to drill for high-grade gold in a region known for multi-million-ounce discoveri...The Tomorrow Investor | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get Paid“I’ve always hated gold. It doesn’t pay dividends… it just sits there.” That’s what one income strategist b...Investors Alley | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myriad Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Myriad Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
